Upfront chemotherapy and subsequent resection for molecularly defined gliomas

Hikaru Sasaki, Yuichi Hirose, Takahito Yazaki, Yohei Kitamura, Makoto Katayama, Tokuhiro Kimura, Hirokazu Fujiwara, Masahiro Toda, Takayuki Ohira, Kazunari Yoshida

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Functional preservation is critical in glioma surgery, and the extent of resection influences survival outcome. Neoadjuvant chemotherapy is a promising option because of its potential to facilitate tumor shrinkage and maximum tumor resection. The object of this study was to assess the utility of the neoadjuvant strategy in a prospective series of gliomas with favorable molecular status. Twenty-six consecutive cases of diffuse gliomas of WHO grade II or III with either 1p19q codeletion or MGMT methylation were treated with upfront chemotherapy following maximal safe removal. In cases of incomplete initial surgery, second-look resection was intended after tumor volume decrease by chemotherapy. Among 22 evaluable cases, chemotherapy led to a median change in the sum of the product of perpendicular diameters of −35 %, and 14 out of the 22 cases (64 %) showed objective response. Second-look resection after tumor volume decrease was performed in 12 out of 19 cases of incomplete initial surgery (GTR/STR 9, removal of residual methionine PET uptake 3). The median progression-free survival among the 22 patients with grade II tumors was 57 months, with some cases showing durable progression-free survival after second-look resection. MIB-1 indices of the second-look resected tumors were lower than those of the initial tumors, and the methylation status of the MGMT gene was unchanged. Neoadjuvant chemotherapy based on molecular guidance often produces significant volume decrease of incompletely resected gliomas. Radical second-look resection is an optional advantage of upfront chemotherapy for chemosensitive gliomas compared with initial radiotherapy.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalJournal of Neuro-Oncology
Volume124
Issue number1
DOIs
Publication statusPublished - 23-08-2015

Fingerprint

Glioma
Drug Therapy
Neoplasms
Tumor Burden
Methylation
Disease-Free Survival
Second-Look Surgery
Methionine
Radiotherapy
Survival
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Sasaki, H., Hirose, Y., Yazaki, T., Kitamura, Y., Katayama, M., Kimura, T., ... Yoshida, K. (2015). Upfront chemotherapy and subsequent resection for molecularly defined gliomas. Journal of Neuro-Oncology, 124(1), 127-135. https://doi.org/10.1007/s11060-015-1817-y
Sasaki, Hikaru ; Hirose, Yuichi ; Yazaki, Takahito ; Kitamura, Yohei ; Katayama, Makoto ; Kimura, Tokuhiro ; Fujiwara, Hirokazu ; Toda, Masahiro ; Ohira, Takayuki ; Yoshida, Kazunari. / Upfront chemotherapy and subsequent resection for molecularly defined gliomas. In: Journal of Neuro-Oncology. 2015 ; Vol. 124, No. 1. pp. 127-135.
@article{28f066af8954409e97174b01b4e0b2bf,
title = "Upfront chemotherapy and subsequent resection for molecularly defined gliomas",
abstract = "Functional preservation is critical in glioma surgery, and the extent of resection influences survival outcome. Neoadjuvant chemotherapy is a promising option because of its potential to facilitate tumor shrinkage and maximum tumor resection. The object of this study was to assess the utility of the neoadjuvant strategy in a prospective series of gliomas with favorable molecular status. Twenty-six consecutive cases of diffuse gliomas of WHO grade II or III with either 1p19q codeletion or MGMT methylation were treated with upfront chemotherapy following maximal safe removal. In cases of incomplete initial surgery, second-look resection was intended after tumor volume decrease by chemotherapy. Among 22 evaluable cases, chemotherapy led to a median change in the sum of the product of perpendicular diameters of −35 {\%}, and 14 out of the 22 cases (64 {\%}) showed objective response. Second-look resection after tumor volume decrease was performed in 12 out of 19 cases of incomplete initial surgery (GTR/STR 9, removal of residual methionine PET uptake 3). The median progression-free survival among the 22 patients with grade II tumors was 57 months, with some cases showing durable progression-free survival after second-look resection. MIB-1 indices of the second-look resected tumors were lower than those of the initial tumors, and the methylation status of the MGMT gene was unchanged. Neoadjuvant chemotherapy based on molecular guidance often produces significant volume decrease of incompletely resected gliomas. Radical second-look resection is an optional advantage of upfront chemotherapy for chemosensitive gliomas compared with initial radiotherapy.",
author = "Hikaru Sasaki and Yuichi Hirose and Takahito Yazaki and Yohei Kitamura and Makoto Katayama and Tokuhiro Kimura and Hirokazu Fujiwara and Masahiro Toda and Takayuki Ohira and Kazunari Yoshida",
year = "2015",
month = "8",
day = "23",
doi = "10.1007/s11060-015-1817-y",
language = "English",
volume = "124",
pages = "127--135",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Sasaki, H, Hirose, Y, Yazaki, T, Kitamura, Y, Katayama, M, Kimura, T, Fujiwara, H, Toda, M, Ohira, T & Yoshida, K 2015, 'Upfront chemotherapy and subsequent resection for molecularly defined gliomas', Journal of Neuro-Oncology, vol. 124, no. 1, pp. 127-135. https://doi.org/10.1007/s11060-015-1817-y

Upfront chemotherapy and subsequent resection for molecularly defined gliomas. / Sasaki, Hikaru; Hirose, Yuichi; Yazaki, Takahito; Kitamura, Yohei; Katayama, Makoto; Kimura, Tokuhiro; Fujiwara, Hirokazu; Toda, Masahiro; Ohira, Takayuki; Yoshida, Kazunari.

In: Journal of Neuro-Oncology, Vol. 124, No. 1, 23.08.2015, p. 127-135.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Upfront chemotherapy and subsequent resection for molecularly defined gliomas

AU - Sasaki, Hikaru

AU - Hirose, Yuichi

AU - Yazaki, Takahito

AU - Kitamura, Yohei

AU - Katayama, Makoto

AU - Kimura, Tokuhiro

AU - Fujiwara, Hirokazu

AU - Toda, Masahiro

AU - Ohira, Takayuki

AU - Yoshida, Kazunari

PY - 2015/8/23

Y1 - 2015/8/23

N2 - Functional preservation is critical in glioma surgery, and the extent of resection influences survival outcome. Neoadjuvant chemotherapy is a promising option because of its potential to facilitate tumor shrinkage and maximum tumor resection. The object of this study was to assess the utility of the neoadjuvant strategy in a prospective series of gliomas with favorable molecular status. Twenty-six consecutive cases of diffuse gliomas of WHO grade II or III with either 1p19q codeletion or MGMT methylation were treated with upfront chemotherapy following maximal safe removal. In cases of incomplete initial surgery, second-look resection was intended after tumor volume decrease by chemotherapy. Among 22 evaluable cases, chemotherapy led to a median change in the sum of the product of perpendicular diameters of −35 %, and 14 out of the 22 cases (64 %) showed objective response. Second-look resection after tumor volume decrease was performed in 12 out of 19 cases of incomplete initial surgery (GTR/STR 9, removal of residual methionine PET uptake 3). The median progression-free survival among the 22 patients with grade II tumors was 57 months, with some cases showing durable progression-free survival after second-look resection. MIB-1 indices of the second-look resected tumors were lower than those of the initial tumors, and the methylation status of the MGMT gene was unchanged. Neoadjuvant chemotherapy based on molecular guidance often produces significant volume decrease of incompletely resected gliomas. Radical second-look resection is an optional advantage of upfront chemotherapy for chemosensitive gliomas compared with initial radiotherapy.

AB - Functional preservation is critical in glioma surgery, and the extent of resection influences survival outcome. Neoadjuvant chemotherapy is a promising option because of its potential to facilitate tumor shrinkage and maximum tumor resection. The object of this study was to assess the utility of the neoadjuvant strategy in a prospective series of gliomas with favorable molecular status. Twenty-six consecutive cases of diffuse gliomas of WHO grade II or III with either 1p19q codeletion or MGMT methylation were treated with upfront chemotherapy following maximal safe removal. In cases of incomplete initial surgery, second-look resection was intended after tumor volume decrease by chemotherapy. Among 22 evaluable cases, chemotherapy led to a median change in the sum of the product of perpendicular diameters of −35 %, and 14 out of the 22 cases (64 %) showed objective response. Second-look resection after tumor volume decrease was performed in 12 out of 19 cases of incomplete initial surgery (GTR/STR 9, removal of residual methionine PET uptake 3). The median progression-free survival among the 22 patients with grade II tumors was 57 months, with some cases showing durable progression-free survival after second-look resection. MIB-1 indices of the second-look resected tumors were lower than those of the initial tumors, and the methylation status of the MGMT gene was unchanged. Neoadjuvant chemotherapy based on molecular guidance often produces significant volume decrease of incompletely resected gliomas. Radical second-look resection is an optional advantage of upfront chemotherapy for chemosensitive gliomas compared with initial radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84937525605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937525605&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1817-y

DO - 10.1007/s11060-015-1817-y

M3 - Article

VL - 124

SP - 127

EP - 135

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -